Across TCGA pan-cancer cohorts, SYNJ2BP mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SYNJ2BP data layer compared with 19 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SYNJ2BP mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SYNJ2BP expression acts as an unfavorable survival marker, although some lineages such as CCRCC and OV show a favorable association.

CCRCC, OV, and HNSC are the cancer types where SYNJ2BP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	1.000	0.908	.014	10	view →
OV	DFS	Median	All	1.000	0.851	.026	4	view →
HNSC	DFS	Tertile	III,IV	0.892	1.000	.016	4	view →
GBM	DFS	Median	All	0.693	0.825	.046	1	view →
LSCC	OS	Median	All	1.000	0.736	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SYNJ2BP tumor-vs-normal RNA expression · all SYNJ2BP data types